Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: Case report

BMC Psychiatry

Volumn 6, Issue , 2006, Pages

  Theleritis, Christos G ^a   Papadimitriou, George N ^a   Papageorgiou, Charalabos C ^a   Dikeos, Dimitris G ^a   Masdrakis, Vasilis ^a   Kostoulas, Constantin ^a   Psarros, Constantin ^a   Soldatos, Constantin R ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CLORAZEPATE; FLUOXETINE; GLUCOSE; METFORMIN; PROLACTIN; RISPERIDONE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ADULT; ARTICLE; BINGE EATING DISORDER; BODY WEIGHT DISORDER; CASE REPORT; CAUCASIAN; DELUSION; DEPRESSION; DIABETES CONTROL; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCREASED APPETITE; POLYDIPSIA; POLYURIA; REMISSION; SCHIZOPHRENIA; SYMPTOMATOLOGY; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BULIMIA; DEPRESSION; DIABETES MELLITUS; FEMALE; FLUOXETINE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33749001422     PISSN: 1471244X     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-6-37     Document Type: Article

References (32)

1. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60(6):553-64.
2. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao, JK: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-23.
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156(11):1686-96.
4. Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, Lippmann S: Body weight changes associated with psychopharmacology. Psychiatric Services 2002, 53:842-7.
5. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diab Care 2004, 27(2):596-601.
6. Kane JM, Barett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S, Newcomer JW: Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004, 65(11):1447-55.
7. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH: Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004, 65(Suppl 7):S4-18.
8. Asher-Svanum H, Stensland M, Zhao Z, Kinon BJ: Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005, 5:3.
9. Haddad P: Weight changes with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005, 19(Suppl 6):16-27.
10. Newcomer JW: Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNC Drugs 2005, 19(Suppl 1):1-93.
11. Henderson DC: Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005, 66(Suppl 6):11-20.
12. Gentile S: Long-term treatment with atypical antipsychotics and the risk of weight gain. A literature analysis. Drug Safety 2006, 29(4):303-19.
13. Papadimitriou GN, Theleritis CG, Dikeos DG, Psarros C, Soldatos CR: Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient. Int Clin Psychopharmacol 2006; 21(3):181-184.
14. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. The Risperidone Study Group. Br J Psychiatry 1995, 166(6):712-26.
15. Möller H-J: Risperidone: A review. Expert Opin Pharmacother 2005, 6(5):803-18.
16. Csernasky JG, Mahmoud R, Brenner R, the Risperidone-USA-79 Study Group: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002, 346(1):16-22.
17. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G, Early Psychosis Global Working Group: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005, 162(5):947-53.
18. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC: Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005, 62(1):19-28.
19. Koller EA, Cross JT, Doraiswamy PM, Schneider BS: Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003, 23(9):735-44.
20. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, Sundell KL, Kim Y, Beasley CM Jr: Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999, 156(8):1170-6.
21. Harvey BH, Bouwer CD: Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol 2000, 23(2):90-97.
22. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996, 334(9):574-579.
23. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diab Care 2004, 27(1):155-161.
24. Werneke U, Taylor D, Sanders TAB: Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 2002, 17(4):145-60.
25. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 2004, 24(4):429-36.
26. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry 2001, 62(4):231-8.
27. Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH: Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry 2003, 64(3):316-20.
28. Kishi T, Elmquist JK: Body weight is regulated by the brain: a link between feeding and emotion. Mol Psychiatry 2005, 10(2):132-46.
29. Grilo CM, Masheb RM, Wilson GT: Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder. A randomized double-blind placebo-controlled comparison. Biol Psychiatry 2005, 57(3):301-9.
30. Baptista T, Hernandez L, Prieto LA, Boyero EC, de Medoza S: Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 2001, 62(8):653-5.
31. Tighe S, Dinan T: An overview of the central control of weight regulation and the effect of antipsychotic medication. J Psychopharmacol 2005, 19(Suppl 6):36-46.
32. Bushe C, Haddad P, Peveler R, Pendlebury J: The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005, 19(Suppl 6):28-35.